CommercialCoverageMedium impact
08.02.35, Drugs, Biologics, or Gene Therapies with an Accelerated Approval
Independence Blue Cross·Oncology, Rheumatology, Neurology +4 more·Pharmacy
Effective date
Nov 12, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross has reissued their policy for drugs, biologics, or gene therapies with accelerated FDA approval. The policy will be effective November 12, 2025, but specific changes to coverage criteria, prior authorization requirements, or billing procedures are not detailed in the summary provided.
Action Required
By November 12, 2025: Billing team must review the full policy document at the provided URL to identify specific changes to coverage criteria, prior authorization requirements, or billing procedures for accelerated approval drugs, biologics, and gene therapies. Update billing system rules and prior authorization workflows as needed based on the detailed policy content.